A Phase 1, Open-Label, Dose-escalation trial of CD33xCD3 Bispecific Antibody in Pediatric patients with Relapsed of Refractory Acute Myeloid Leukemia - COG ADVL 2111

Grant

Awarded By

Total Award Amount

  • 68000.00

    • Direct Costs

  • 50000.00

    • Sponsor Award Id

    • Contributor

  • Matthew Kutny M.D.   Principal Investigator